After vaccination with Covishield, healthy volunteers will be checked by expert physicians and randomised to receive either vaccine or vaccine plus Ashwagandha in this 1500 sample size prospective, double-blind, parallel-group, placebo-controlled and two-arm study. (Representational/File) THE PUBLICATION of a study protocol that aims to understand the potential of Ashwagandha – a traditional ayurvedic herbal drug for boosting immunity to improve Covid-19 vaccine response – in a top clinical research journal is being viewed as a landmark global recognition for ayurved and modern medicine integrative research.
Scientists are enthused over the publication of the protocol in a high-ranking clinical research journal: Frontiers in Medicine. The study is funded by Central Council for Research in Ayurvedic Sciences (CCRAS) and Ministry of AYUSH, Government of India.
Rajesh Kotecha, secretary, Ministry of AYUSH, told The Indian Express that this study adopts a novel approach and the scientific community is eager to explore the impact on the current vaccination programme by improving immunogenicity and protection with simple and safe intervention. This hypothesis of better efficacy with a combination of vaccine (Covishield) and Ashwagandha is being tested in a drug trial launched by Ministry of AYUSH and its research wing (CCRAS) in several clinical centres across Pune, Mumbai, Nagpur, Delhi and Jaipur, among other cities.
After vaccination with Covishield, healthy volunteers will be checked by expert physicians and randomised to receive either vaccine or vaccine plus Ashwagandha in this 1500 sample size prospective, double-blind, parallel-group, placebo-controlled and two-arm study.
“The main outcome measure is early and persistent long-term immunogenicity as measured by SARS-CoV-2 spike (S1) and RBD-specific IgG antibody titres. Several other measures include safety, breakthrough infections, quality of life and cellular immune memory cell responses. Efficacy and safety will be assessed at several time points during this 24-week study, which can be extended up to 48 weeks in case of early success with the Ashwagandha-Covishield combination,” said Dr Arvind Chopra, director of the Centre for Rheumatic Diseases, Pune, who has authored several research protocols for completed Ayurveda drug trials in Covid-19 and is the first author of the study.
Publication of study protocols ensures greater transparency in the research process, study researchers said.
Prof Bhushan Patwardhan, national AYUSH research professor and chair of AYUSH Covid task force, is the senior author and along with a team at Pune University, he has carried out research on Ashwagandha.
“Ashwagandha is a time-honoured traditional Ayurvedic herbal drug for boosting immunity and restoring deranged immune response, which characterises several autoimmune and infectious diseases including Covid-19. Host immunity is pivotal for prevention and recovery…,” said Dr Patwardhan.
- The Indian Express website has been rated GREEN for its credibility and trustworthiness by Newsguard, a global service that rates news sources for their journalistic standards.
